Abstract 17370: Perceptions of Patients with Stable Coronary Disease and Adherence to Dual Antiplatelet Therapy 30-Days after Coronary Angiography
Background: Platelet inhibition is an important focus of medical management in patients with stable coronary artery disease (CAD), with multiple patient-related factors linked to dual antiplatelet therapy (DAPT) non-adherence. However, little is known about illness perceptions surrounding the use of antiplatelet medications and whether they differ in patients who are treated with medical and/or interventional approaches. The purpose of this study was to compare differences in illness perceptions of patients with stable CAD and report adherence to DAPT 30 days after initiating treatment.
Methods: Subjects (n=180) were recruited after coronary angiography and optimal medical therapy (OMT) (n=90) and percutaneous coronary intervention and optimal medical therapy (PCI/OMT) (n=90). The Illness Perception Questionnaire-Revised (IPQ-R) was administered at baseline and 30-days after treatment, with a response rate of 52.8% (n=95) at 30-days. Patients were predominantly male (71.7%) with a mean age of 65.1 (±8.3). Adherence to DAPT (aspirin and thienopyridine) at 30-days was collected using a health history update.
Results: Adherence data (mean ± SEM) and IPQ-R subscale Timeline scores are shown. Adherent PCI/OMT subjects had significantly higher acute/chronic timeline (aspirin: t=-3.5, p=.01; thienopyridine: t=-4.3, p=<.001) and timeline cyclical scores (aspirin t=-2.5, p=.01; thienopyridine: t=-2.8, p=.009).
Conclusions: Overall, patients who perceived their illness to be chronic instead of acute were more likely to remain adherent to their antiplatelet medications 30 days after treatment. Higher timeline cyclical scores were reported in patients who were adherent to antiplatelet medications after PCI/OMT, which suggests the influence of continued symptoms as an indicator for adherence. A tailored educational approach regarding dual-antiplatelet medications may be needed to reinforce long-term therapy in this population of patients.
- Antiplatelet drugs
- Percutaneous coronary intervention
- Coronary artery disease
- Cardiovascular disease
- © 2011 by American Heart Association, Inc.